title: Recurrent leakage after Visudyne photodynamic therapy for the treatment of circumscribed choroidal hemangioma.
abstract: BACKGROUND
  To report on the recurrence of serous retinal detachment following verteporfin photodynamic therapy for circumscribed choroidal hemangioma.
  
  
  METHODS
  A single-center chart review was performed for patients with circumscribed choroidal hemangioma (CCH) treated with Visudyne (verteporfin injection; QLT Ophthalmics, Menlo Park, CA) photodynamic therapy (PDT). Initial and post-treatment visual acuity, ultrasound and ocular coherence tomography were evaluated.
  
  
  RESULTS
  Four patients who were treated with PDT for symptomatic serous retinal detachment secondary to CCH were managed for recurrent leakage and followed for an average of 47.5 months. Two patients required three re-treatments and two required four re-treatments for recurrent detachment. Average time to re-treatment was 23.4 months, with successive re-treatment intervals decreasing to 13 months, then 9.5 months, and finally 3.5 months.
  
  
  CONCLUSIONS
  Visudyne PDT is a successful initial treatment modality for CCH with serous retinal detachment; however, those patients who require multiple re-treatments may experience recurrent leakage at more frequent intervals.
authors.affiliation: Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, CA 90095, USA.
authors.forename: Robert M
authors.initials: RM
authors.lastname: Beardsley
authors.forename: Colin A
authors.initials: CA
authors.lastname: McCannel
authors.forename: Tara A
authors.initials: TA
authors.lastname: McCannel
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy / Q000209:etiology; D002830:Choroid Neoplasms / Q000150:complications*; D005122:Exudates and Transudates; D006391:Hemangioma / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011166:Porphyrins / Q000008:administration & dosage*; D012008:Recurrence; D012163:Retinal Detachment / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D019233:Retreatment / Q000706:statistics & numerical data; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin